255 related articles for article (PubMed ID: 25583979)
1. The clinical role and cost-effectiveness of long-acting antiretroviral therapy.
Ross EL; Weinstein MC; Schackman BR; Sax PE; Paltiel AD; Walensky RP; Freedberg KA; Losina E
Clin Infect Dis; 2015 Apr; 60(7):1102-10. PubMed ID: 25583979
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age.
Ciaranello AL; Doherty K; Penazzato M; Lindsey JC; Harrison L; Kelly K; Walensky RP; Essajee S; Losina E; Muhe L; Wools-Kaloustian K; Ayaya S; Weinstein MC; Palumbo P; Freedberg KA
AIDS; 2015 Jun; 29(10):1247-59. PubMed ID: 25870982
[TBL] [Abstract][Full Text] [Related]
3. Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis.
Boyer S; March L; Kouanfack C; Laborde-Balen G; Marino P; Aghokeng AF; Mpoudi-Ngole E; Koulla-Shiro S; Delaporte E; Carrieri MP; Spire B; Laurent C; Moatti JP;
Lancet Infect Dis; 2013 Jul; 13(7):577-86. PubMed ID: 23602084
[TBL] [Abstract][Full Text] [Related]
4. Does combining antiretroviral agents in a single dosage form enhance quality of life of HIV/AIDS patients? A cost-utility study.
Ganguli A; Wang J; Gourley DR
Res Social Adm Pharm; 2012; 8(2):157-65. PubMed ID: 21712147
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire.
Goldie SJ; Yazdanpanah Y; Losina E; Weinstein MC; Anglaret X; Walensky RP; Hsu HE; Kimmel A; Holmes C; Kaplan JE; Freedberg KA
N Engl J Med; 2006 Sep; 355(11):1141-53. PubMed ID: 16971720
[TBL] [Abstract][Full Text] [Related]
6. Expanded screening for HIV in the United States--an analysis of cost-effectiveness.
Paltiel AD; Weinstein MC; Kimmel AD; Seage GR; Losina E; Zhang H; Freedberg KA; Walensky RP
N Engl J Med; 2005 Feb; 352(6):586-95. PubMed ID: 15703423
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of integrating methadone maintenance and antiretroviral treatment for HIV-positive drug users in Vietnam's injection-driven HIV epidemics.
Tran BX; Ohinmaa A; Duong AT; Nguyen LT; Vu PX; Mills S; Houston S; Jacobs P
Drug Alcohol Depend; 2012 Oct; 125(3):260-6. PubMed ID: 22436971
[TBL] [Abstract][Full Text] [Related]
8. Budget impact of antiretroviral therapy in a French clinic cohort.
Papot E; Landman R; Louni F; Charpentier C; Peytavin G; Certain A; Fradet C; Castro DR; Preau M; Goujard C; Yeni P; Yazdanpanah Y;
AIDS; 2017 Jun; 31(9):1271-1279. PubMed ID: 28323753
[TBL] [Abstract][Full Text] [Related]
9. Treatment Failure in HIV-Infected Children on Second-line Protease Inhibitor-Based Antiretroviral Therapy.
Suaysod R; Ngo-Giang-Huong N; Salvadori N; Cressey TR; Kanjanavanit S; Techakunakorn P; Krikajornkitti S; Srirojana S; Laomanit L; Chalermpantmetagul S; Lallemant M; Le Cœur S; McIntosh K; Traisathit P; Jourdain G
Clin Infect Dis; 2015 Jul; 61(1):95-101. PubMed ID: 25838288
[TBL] [Abstract][Full Text] [Related]
10. Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies.
Hamers RL; Sigaloff KC; Wensing AM; Wallis CL; Kityo C; Siwale M; Mandaliya K; Ive P; Botes ME; Wellington M; Osibogun A; Stevens WS; Rinke de Wit TF; Schuurman R;
Clin Infect Dis; 2012 Jun; 54(11):1660-9. PubMed ID: 22474222
[TBL] [Abstract][Full Text] [Related]
11. The lifetime cost of current human immunodeficiency virus care in the United States.
Schackman BR; Gebo KA; Walensky RP; Losina E; Muccio T; Sax PE; Weinstein MC; Seage GR; Moore RD; Freedberg KA
Med Care; 2006 Nov; 44(11):990-7. PubMed ID: 17063130
[TBL] [Abstract][Full Text] [Related]
12. [Analysis of costs and cost-effectiveness of preferred GESIDA/National AIDS Plan regimens for initial antiretroviral therapy in human immunodeficiency virus infected adult patients in 2013].
Blasco AJ; Llibre JM; Arribas JR; Boix V; Clotet B; Domingo P; González-García J; Knobel H; López JC; Lozano F; Miró JM; Podzamczer D; Santamaría JM; Tuset M; Zamora L; Lázaro P; Gatell JM;
Enferm Infecc Microbiol Clin; 2013 Nov; 31(9):568-78. PubMed ID: 23969276
[TBL] [Abstract][Full Text] [Related]
13. Improved retention associated with community-based accompaniment for antiretroviral therapy delivery in rural Rwanda.
Franke MF; Kaigamba F; Socci AR; Hakizamungu M; Patel A; Bagiruwigize E; Niyigena P; Walker KD; Epino H; Binagwaho A; Mukherjee J; Farmer PE; Rich ML
Clin Infect Dis; 2013 May; 56(9):1319-26. PubMed ID: 23249611
[TBL] [Abstract][Full Text] [Related]
14. When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.
Badri M; Cleary S; Maartens G; Pitt J; Bekker LG; Orrell C; Wood R
Antivir Ther; 2006; 11(1):63-72. PubMed ID: 16518961
[TBL] [Abstract][Full Text] [Related]
15. The costs and benefits of Option B+ for the prevention of mother-to-child transmission of HIV.
Gopalappa C; Stover J; Shaffer N; Mahy M
AIDS; 2014 Jan; 28 Suppl 1():S5-14. PubMed ID: 24468947
[TBL] [Abstract][Full Text] [Related]
16. [Cost of Illness of HIV Patients under Anteretroviral Therapy in Germany - Results of the 48-Week Interim Analysis of the Prospective Multicentre Observational Study 'CORSAR'].
Kuhlmann A; Mittendorf T; Hower M; Heiken H; Gerschmann S; Klauke S; Lutz T; Bogner J; Degen O; van Lunzen J; Bachmann C; Stellbrink HJ; Schmidt W; Leistner I; Mahlich J; Ranneberg B; Stoll M
Gesundheitswesen; 2015 Jun; 77(6):e133-42. PubMed ID: 25247761
[TBL] [Abstract][Full Text] [Related]
17. HIV cure strategies: how good must they be to improve on current antiretroviral therapy?
Sax PE; Sypek A; Berkowitz BK; Morris BL; Losina E; Paltiel AD; Kelly KA; Seage GR; Walensky RP; Weinstein MC; Eron J; Freedberg KA
PLoS One; 2014; 9(11):e113031. PubMed ID: 25397616
[TBL] [Abstract][Full Text] [Related]
18. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy.
Sanders GD; Bayoumi AM; Sundaram V; Bilir SP; Neukermans CP; Rydzak CE; Douglass LR; Lazzeroni LC; Holodniy M; Owens DK
N Engl J Med; 2005 Feb; 352(6):570-85. PubMed ID: 15703422
[TBL] [Abstract][Full Text] [Related]
20. The cost effectiveness of antiretroviral treatment strategies in resource-limited settings.
Bishai D; Colchero A; Durack DT
AIDS; 2007 Jun; 21(10):1333-40. PubMed ID: 17545710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
